For a closer look

Research Library

Read what researchers wanted to find out and what it means in everyday words. Open the details if you want to see how a study was done. The product pages have a shorter explanation.

Original sources checked on 4 October 2026. AI-assisted editorial summaries, not a systematic review or an independent medical assessment.

Showing research linked to Tesamorelin.

Back to the short explanation

1 study found

Research context

Less fat inside the liver in a specific group

People living with HIV and fatty liver disease.

What did they want to find out?

Did liver fat change after 12 months compared with placebo?

What did researchers observe?

Tesamorelin produced a larger average reduction in liver fat.

What does this mean for you?

This measures fat inside the liver; it does not establish an equivalent reduction in total body fat.

What we still do not know

Not generalizable to people without HIV. The primary abstract was checked here, not every supplement or analysis.

Show study details

Original sources checked on 4 October 2026. AI-assisted editorial summaries, not a systematic review or an independent medical assessment.

Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial

The Lancet HIV · 2019

How it was studied

Randomized, double-blind, placebo-controlled trial; main comparison over 12 months.. 61 people enrolled with HIV and fatty liver; 60 received intervention or placebo..

Study finding

The difference in liver-fat change was −4.1 percentage points versus placebo, corresponding to a 37% relative reduction.

Study limitations

Small, specific population. Local injection-site complaints were more common; the abstract does not settle individual safety or long-term liver outcomes.

Who is behind the study?

Identified authors
Takara L. Stanley, Lindsay T. Fourman, Meghan N. Feldpausch, Julia Purdy, Isabel Zheng, Chelsea S. Pan, Julia Aepfelbacher, Colleen Buckless, Andrew Tsao, Anela Kellogg, Karen Branch, Hang Lee, Chia-Ying Liu, Kathleen E. Corey, Raymond T. Chung, Martin Torriani, David E. Kleiner, Colleen M. Hadigan, Steven K. Grinspoon
Funding and involvement
National Institutes of Health and National Institute of Allergy and Infectious Diseases.
Disclosed interests and verification limits
Not confirmed from the accessed source: the indexed primary abstract was checked, not the full disclosure statement.

Terms explained

Hepatic fat fraction
The measured proportion of fat inside the liver.
Relative reduction
Change compared with the starting value; different from percentage points.

Read the source and its limitations. A reference does not automatically validate a commercial product.

Read the source